Karl Leo serves as Executive at Monopar Therapeutics, where they oversee executive responsibilities. Since joining the company, Karl Leo has executed 2 insider transactions totaling $1.3M, demonstrating a bullish approach to their equity position. Their most recent transaction on Dec 18, 2019 involved purchasing 156,250 shares valued at $1.3M.
Karl Leo currently holds 156,250 shares of Monopar Therapeutics (MNPR), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Karl Leo has been a net buyer of MNPR stock. They have purchased $1.3M and sold $0 worth of shares.
Karl Leo's most recent insider trade was on Dec 18, 2019, when they purchased 156,250 shares at $8.00 per share.
Get notified when new Form 4 filings are submitted
| $8.00 |
| Discretionary |